1. Home
  2. CHW vs ARVN Comparison

CHW vs ARVN Comparison

Compare CHW & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Global Dynamic Income Fund

CHW

Calamos Global Dynamic Income Fund

HOLD

Current Price

$8.50

Market Cap

563.9M

Sector

Finance

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$9.53

Market Cap

600.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHW
ARVN
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
563.9M
600.2M
IPO Year
2007
2018

Fundamental Metrics

Financial Performance
Metric
CHW
ARVN
Price
$8.50
$9.53
Analyst Decision
Buy
Analyst Count
0
19
Target Price
N/A
$15.05
AVG Volume (30 Days)
133.4K
860.9K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.84
EPS
N/A
1.70
Revenue
N/A
$262,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.46
Revenue Growth
N/A
N/A
52 Week Low
$6.98
$6.97
52 Week High
$9.18
$14.22

Technical Indicators

Market Signals
Indicator
CHW
ARVN
Relative Strength Index (RSI) 48.05 60.60
Support Level $8.45 $7.90
Resistance Level $8.81 $9.70
Average True Range (ATR) 0.10 0.32
MACD -0.01 -0.01
Stochastic Oscillator 38.75 79.41

Price Performance

Historical Comparison
CHW
ARVN

About CHW Calamos Global Dynamic Income Fund

Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities, and alternative investments.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: